STOCKS TELEGRAPH

Author: ST Staff

3 Stocks That Could See Momentum: Passage Bio (PASG), Cardiol Therapeutics (CRDL), SciSparc (SPRC)

With healthcare innovation continuing to drive momentum across the biotech sector, investors are closely monitoring companies that combine advancing clinical pipelines with measurable development progress. As multiple small-cap healthcare firms approach important operational and regulatory milestones, market participants remain focused on identifying companies with differentiated science and meaningful upside potential.

Passage Bio Inc (PASG)

Witnessing the stock’s movement on the chart, on May 13, 2026, Passage Bio Inc (NASDAQ: PASG) set off with pace as it heaved 9.74% to $5.52. During the day, the stock rose to $5.74 and sank to $5.00. Taking a long-term approach, PASG posted a 52-week range of $3.93-$20.00.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 24.41%. Meanwhile, its Annual Earnings per share during the time was 24.41%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 35.80%. This publicly-traded company’s shares outstanding now amount to $3.21 million, simultaneously with a float of $3.11 million. The organization now has a market capitalization of $17.71 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is reinforcing its long-term investment thesis through disciplined operational execution, focused capital allocation, and a commercialization strategy designed to support sustainable growth. In the biotech sector, maintaining financial flexibility while advancing multiple development programs remains an important factor in reducing execution risk and supporting shareholder confidence.

Market Momentum

As of May 13, 2026, CRDL closed at $1.36, up 0.74%, with trading volume of 504,589 shares compared to an average volume of 686,598 shares. The company currently maintains a market capitalization of $151.885M and a beta of 0.43, reflecting relatively moderate volatility for a clinical-stage biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 indicates substantial upside potential tied to future clinical and strategic milestones.

Financial Positioning

Cardiol has previously stated that its existing capital resources are expected to support operations into 2027, providing the company with flexibility to continue advancing the Phase III MAVERIC trial and support broader pipeline development activities. This funding runway may help reduce near-term dilution concerns while allowing management to remain focused on operational execution.

Commercialization Strategy

Management has emphasized a partnership-oriented commercialization model that could allow Cardiol to leverage the regulatory expertise, infrastructure, and global reach of larger pharmaceutical companies. Such a strategy may accelerate future market entry opportunities while enabling the company to remain focused on clinical innovation in inflammatory cardiovascular disease.

Outlook

With continued clinical advancement, disciplined financial management, and a pragmatic commercialization approach, Cardiol appears increasingly well-positioned to pursue long-term value creation as it advances toward future regulatory and partnership milestones.

SciSparc Ltd (SPRC)

SciSparc Ltd (NASDAQ: SPRC) opened the trading on May 13, 2026, with a bit cautious approach as it glided -7.55% to $5.02. During the day, the stock rose to $5.45 and sank to $5.02. Taking a long-term approach, SPRC posted a 52-week range of $2.98-$80.10.

The Healthcare sector firm’s twelve-monthly sales growth has been -8.23% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time were -8.23%. This publicly-traded company’s shares outstanding now amount to $0.57 million, simultaneously with a float of $0.52 million. The organization now has a market capitalization of $2.88 million.

May 14, 2026
3 Stocks That Could Stand Out: Cardiol Therapeutics (CRDL), Immuron (IMRN), Retractable Technologies (RVP)

Clinical-stage biotech companies are once again seeing increased investor interest as the industry moves into a period defined by major trial milestones, FDA interactions, and growing demand for innovative therapies targeting underserved patient populations. Several emerging healthcare companies are positioning themselves for potentially transformative development events that could shape future valuation trends.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is increasingly differentiating itself through a science-driven approach focused on inflammation as a key contributor to cardiovascular disease. As researchers continue identifying inflammatory signaling as an important driver of cardiac injury and disease progression, targeted anti-inflammatory therapies are gaining greater relevance across the healthcare sector.

Market Momentum

As of May 13, 2026, CRDL closed at $1.36, up 0.74%, with trading volume of 504,589 shares versus an average volume of 686,598 shares. The company currently holds a market capitalization of $151.885M and a beta of 0.43, reflecting relatively controlled volatility compared to many development-stage biotech peers. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 suggests meaningful upside potential tied to future clinical and regulatory progress.

Mechanism of Action

Cardiol’s lead therapies are designed to target inflammatory signaling pathways associated with cardiovascular injury and chronic disease progression. By modulating inflammasome activity and reducing pro-inflammatory cytokines such as IL-1 and IL-6, the company aims to address underlying inflammatory drivers linked to recurrent pericarditis, myocarditis, and other cardiovascular disorders.

Strategic Differentiation

Unlike broader immunosuppressive approaches, Cardiol’s strategy is intended to selectively reduce harmful inflammation while preserving normal immune system function. This differentiated profile may offer advantages in long-term safety and tolerability, particularly for patients requiring extended treatment duration in chronic cardiovascular conditions.

Outlook

As inflammation continues gaining recognition as an important therapeutic target within cardiovascular medicine, Cardiol’s mechanism-focused platform could strengthen its long-term strategic positioning. Continued clinical validation may further support investor confidence and future partnership opportunities.

Immuron Limited ADR (IMRN)

As of May 13, 2026, Immuron Limited ADR (NASDAQ: IMRN) got off with the flyer as it spiked 11.11% to $0.89. During the day, the stock rose to $0.98 and sank to $0.81. Taking a more long-term approach, IMRN posted a 52-week range of $0.68-$2.39.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -5.64%. Meanwhile, its Annual Earnings per share during the time were -5.64%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 98.57%. This publicly-traded company’s shares outstanding now amount to $8.17 million, simultaneously with a float of $3.25 million. The organization now has a market capitalization of $7.27 million.

Retractable Technologies Inc (RVP)

Retractable Technologies Inc (NYSEAMERICAN: RVP) flaunted a slowness of -0.31% at $0.7, as the Stock market unbolted on May 13, 2026. During the day, the stock rose to $0.73 and sank to $0.66. Taking a long-term approach, RVP posted a 52-week range of $0.60-$1.14.

This publicly-traded company’s shares outstanding now amount to $29.94 million, simultaneously with a float of $12.21 million. The organization now has a market capitalization of $20.96 million. Its Quick Ratio in the last reported quarter now stands at 4.78. Another valuable indicator worth pondering is a publicly-traded company’s price-to-sales ratio for the trailing twelve months, which is currently 0.55.

May 14, 2026
3 Stocks Catching Market Interest: Whitehawk Therapeutics (WHWK), Cardiol Therapeutics (CRDL), SS Innovations International (SSII)

Within the healthcare industry, long-term investor interest is frequently supported by continued clinical development and the demonstration of tangible progress across research programs. Despite periods of market uncertainty, companies that focus on addressing unmet medical needs tend to maintain stronger engagement from investors seeking transformative treatment potential.

Whitehawk Therapeutics Inc (WHWK)

Whitehawk Therapeutics Inc (NASDAQ: WHWK) established an initial surge of 3.16% at $3.92, as the Stock market unbolted on May 12, 2026. During the day, the stock rose to $3.96 and sank to $3.79. Taking a more long-term approach, WHWK posted a 52-week range of $1.57-$4.48.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 58.28%. Meanwhile, its Annual Earnings per share during the time was 58.28%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is -294.55%. This publicly-traded company’s shares outstanding now amount to $47.20 million, simultaneously with a float of $30.63 million. The organization now has a market capitalization of $193.85 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to broaden its cardiovascular pipeline by targeting inflammatory diseases that currently have limited treatment options. As scientific understanding of inflammation-driven heart disease expands, companies capable of developing therapies across multiple cardiac indications may be positioned for larger long-term growth opportunities.

Market Momentum

As of May 12, 2026, CRDL closed at $1.35, up 1.12%, with trading volume of 353,515 shares versus an average volume of 689,450 shares. The company currently carries a market capitalization of $150.768M and a beta of 0.43, indicating relatively controlled volatility for a development-stage biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.39 suggests meaningful upside potential tied to future clinical progress.

Clinical Expansion: Acute Myocarditis

Cardiol’s Phase II ARCHER study evaluated CardiolRx™ in acute myocarditis, a condition involving inflammation of the heart muscle that can lead to arrhythmias, heart failure, and long-term cardiac damage. Clinical findings demonstrated reductions in cardiac inflammation alongside structural improvements, including decreases in left ventricular mass, a key indicator associated with cardiac remodeling and recovery.

Addressing Unmet Need

Current treatment approaches for myocarditis are largely supportive, with limited therapies directly targeting the inflammatory drivers of disease progression. Cardiol’s strategy of addressing underlying inflammation may provide a differentiated therapeutic approach for patients who currently face few targeted treatment options.

Outlook

As Cardiol continues building evidence across multiple inflammatory cardiovascular diseases, successful development in myocarditis could significantly expand the company’s long-term commercial opportunity and strengthen the broader value of its clinical platform.

SS Innovations International Inc (SSII)

Witnessing the stock’s movement on the chart, on May 12, 2026, SS Innovations International Inc (NASDAQ: SSII) set off with pace as it heaved 0.74% to $4.11. During the day, the stock rose to $4.22 and sunk to $4.01. Taking a more long-term approach, SSII posted a 52-week range of $3.02-$11.87.

The Healthcare sector firm’s twelve-monthly sales growth has been 33.24% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time was 33.24%. This publicly-traded company’s shares outstanding now amount to $194.17 million, simultaneously with a float of $32.59 million. The organization now has a market capitalization of $822.95 million.

May 13, 2026
3 Stocks That Could Climb Higher: GH Research (GHRS), Nutex Health (NUTX), Cardiol Therapeutics (CRDL)

Across biotechnology and healthcare markets, investor sentiment is closely influenced by the pace and significance of clinical milestones achieved by emerging therapies. While short-term volatility is not uncommon, sustained market interest is often centered on solutions that address critical gaps in current standards of care.

GH Research PLC (GHRS)

GH Research PLC (NASDAQ: GHRS) opened trading on May 12, 2026, with great promise as it jumped 1.32% to $21.54. During the day, the stock rose to $21.75 and sank to $20.89. Taking a long-term approach, GHRS posted a 52-week range of $9.46-$24.66.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 162.03%. Meanwhile, its Annual Earnings per share during the time were -162.03%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is -84.53%. This publicly-traded company’s shares outstanding now amount to $62.03 million, simultaneously with a float of $49.37 million. The organization now has a market capitalization of $1.48 billion.

Nutex Health Inc (NUTX)

Nutex Health Inc (NASDAQ: NUTX) started the day on May 12, 2026, with a price increase of 1.96% at $135.48. During the day, the stock rose to $135.53 and sank to $128.01. Taking a long-term approach, NUTX posted a 52-week range of $77.21-$193.07.

Nevertheless, the stock’s Earnings Per Share (EPS) this year is 100.57%. This publicly-traded company’s shares outstanding now amount to $6.95 million, simultaneously with a float of $4.74 million. The organization now has a market capitalization of $932.28 million. Its Quick Ratio in the last reported quarter now stands at 3.12.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved markets. By expanding beyond recurrent pericarditis, the company is positioning itself to participate in areas where inflammation and fibrosis remain important drivers of disease progression.

Market Momentum

As of May 12, 2026, CRDL closed at $1.35, up 1.12%, with trading volume of 353,515 shares compared to an average volume of 689,450 shares. The company currently maintains a market capitalization of $150.768M and a beta of 0.43, reflecting relatively moderate volatility compared to many small-cap biotech peers. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.39 suggests substantial upside potential tied to pipeline advancement and future clinical milestones.

Pipeline Development: CRD-38

Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, two biological mechanisms strongly associated with declining cardiac function and progressive heart disease.

Market Opportunity

Heart failure represents one of the largest cardiovascular markets globally, affecting millions of patients and generating significant healthcare costs annually. Despite multiple treatment options already available, unmet need remains for therapies capable of directly addressing inflammatory and fibrotic pathways that contribute to disease progression.

Outlook

As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the company’s pipeline may strengthen its long-term positioning within the cardiovascular biotechnology sector.

May 13, 2026
3 Stocks That Could Move Higher: Cardiol Therapeutics (CRDL), Park Dental Partners (PARK), Valneva SE (VALN)

In the evolving healthcare landscape, investor confidence is often shaped by a company’s ability to deliver measurable clinical advancements over time. Although market fluctuations remain a consistent factor, sustained stakeholder attention is generally driven by the promise of innovative therapies that can improve outcomes when existing treatment options remain limited.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is entering a more advanced stage of development as its lead cardiovascular therapy continues progressing through late-stage clinical evaluation. For emerging biotech companies, the transition from early clinical promise to pivotal-stage execution often represents a defining period that can significantly influence long-term valuation.

Market Momentum

As of May 12, 2026, CRDL closed at $1.35, up 1.12%, with trading volume of 353,515 shares compared to an average volume of 689,450 shares. The company currently maintains a market capitalization of $150.768M and a beta of 0.43, reflecting relatively moderate volatility for a clinical-stage biotech stock. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.39 highlights substantial upside potential tied to future clinical and regulatory milestones.

Phase III MAVERIC Progress

Cardiol’s ongoing Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis remains a central focus for investors. The randomized, double-blind, placebo-controlled study has already surpassed 75% patient enrollment and was developed in collaboration with the U.S. Food and Drug Administration following encouraging Phase II discussions.

Clinical Foundation

Earlier Phase II findings demonstrated reductions in pericarditis-related pain, inflammation, and recurrence frequency, while also showing favorable safety and tolerability outcomes. These results have strengthened the clinical rationale for CardiolRx™ as a potential treatment option for patients with recurrent inflammatory heart disease.

Outlook

With late-stage enrollment progressing and prior clinical data continuing to support development, Cardiol appears increasingly well-positioned as it advances toward future regulatory discussions and potential commercialization opportunities.

Park Dental Partners Inc (PARK)

Park Dental Partners Inc (NASDAQ: PARK) started the day on May 12, 2026, with a price increase of 5.16% at $18.96. During the day, the stock rose to $19.29 and sank to $16.75. Taking a long-term approach, PARK posted a 52-week range of $9.53-$21.59.

Nevertheless, the stock’s Earnings Per Share (EPS) this year is -55.33%. This publicly-traded company’s shares outstanding now amount to $4.25 million, simultaneously with a float of $3.82 million. The organization now has a market capitalization of $85.61 million. Its Quick Ratio in the last reported quarter now stands at 1.03.

Valneva SE ADR (VALN)

As of May 12, 2026, Valneva SE ADR (NASDAQ: VALN) started slowly as it slid -4.76% to $6.0. During the day, the stock rose to $6.13 and sunk to $5.76. Taking a long-term approach, VALN posted a 52-week range of $5.06-$12.25.

In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was 0.90%. Meanwhile, its Annual Earnings per share during the time was 0.90%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 40.87%. This publicly-traded company’s shares outstanding now amount to $94.82 million, simultaneously with a float of $89.76 million. The organization now has a market capitalization sitting at $568.92 million.

May 13, 2026
3 Stocks Worth Following Right Now: Cadrenal Therapeutics (CVKD), Cuprina (CUPR), Cardiol Therapeutics (CRDL)

Market behavior in clinical-stage equities is frequently influenced by expectations surrounding upcoming milestones, including enrollment completion, interim analyses, and final data readouts. These events can significantly reshape outlooks, particularly when they occur in pivotal or registration-enabling studies.

Cadrenal Therapeutics Inc (CVKD)

Cadrenal Therapeutics Inc (NASDAQ: CVKD) opened the trading on May 11, 2026, with a bit cautious approach as it glided -9.32% to $5.52. During the day, the stock rose to $6.32 and sank to $5.47. Taking a long-term approach, CVKD posted a 52-week range of $4.21-$16.25.

Nevertheless, the stock’s Earnings Per Share (EPS) this year is 16.82%. This publicly-traded company’s shares outstanding now amount to $2.51 million, simultaneously with a float of $2.23 million. The organization now has a market capitalization of $15.84 million.

Cuprina Holdings (Cayman) Ltd (CUPR)

Cuprina Holdings (Cayman) Ltd (NASDAQ: CUPR) started the day on May 11, 2026, with a price decrease of -3.36% at $0.27. During the day, the stock rose to $0.28 and sank to $0.27. Taking a long-term approach, CUPR posted a 52-week range of $0.24-$9.50.

It was noted that the giant of the Healthcare sector posted annual sales growth of -74.96% over the last 5 years. Meanwhile, its Annual Earnings per share during the time were -74.96%. This publicly-traded company’s shares outstanding now amount to $7.37 million, simultaneously with a float of $7.37 million. The organization now has a market capitalization of $1.99 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term growth narrative through the advancement of next-generation therapies designed to address broader cardiovascular markets. By expanding beyond its lead indication, the company is positioning itself to participate in larger commercial opportunities tied to chronic heart disease and inflammation-driven cardiac dysfunction.

Market Momentum

As of May 11, 2026, CRDL closed at $1.3350, up 1.14%, with trading volume of 370,080 shares versus an average volume of 686,413 shares. The company currently maintains a market capitalization of $149.093M and a beta of 0.43, reflecting relatively moderate volatility for a development-stage biotech company. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 suggests substantial upside potential tied to future pipeline execution.

Pipeline Development: CRD-38

Cardiol is advancing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy targets inflammation and fibrosis, two biological processes strongly associated with progressive cardiac remodeling and declining heart function.

Commercial Opportunity

Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating substantial healthcare costs each year. Despite multiple available therapies, a significant unmet need remains for treatments capable of directly addressing inflammatory and fibrotic disease mechanisms that contribute to long-term progression.

Outlook

As CRD-38 advances toward future clinical development, the program could emerge as a meaningful secondary value driver for Cardiol. Continued progress across both lead and pipeline assets may strengthen the company’s broader strategic positioning within cardiovascular biotechnology.

May 12, 2026
3 Stocks Investors Should Know About: BriaCell Therapeutics (BCTX), Cardiol Therapeutics (CRDL), Oragenics Inc (OGEN)

Healthcare innovation remains a key driver of long-term growth within the life sciences industry, supported by ongoing demand for improved treatment options across chronic and complex diseases. Companies developing differentiated therapies often attract increased attention as they progress through successive phases of clinical validation.

BriaCell Therapeutics Corp (BCTX)

BriaCell Therapeutics Corp (NASDAQ: BCTX) flaunted a slowness of -0.72% at $4.16, as the Stock market unbolted on May 11, 2026. During the day, the stock rose to $4.31 and sank to $4.13. Taking a long-term approach, BCTX posted a 52-week range of $3.60-$37.20.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 39.57%. Meanwhile, its Annual Earnings per share during the time was 39.57%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 93.92%. This publicly-traded company’s shares outstanding now amount to $7.25 million, simultaneously with a float of $7.15 million. The organization now has a market capitalization of $30.16 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is increasingly differentiating itself through a mechanism-focused strategy aimed at treating cardiovascular inflammation without broadly suppressing immune function. As inflammation becomes a more established therapeutic target in heart disease, companies with targeted approaches may gain strategic advantages within the evolving cardiovascular treatment landscape.

Market Momentum

As of May 11, 2026, CRDL closed at $1.3350, up 1.14%, with trading volume of 370,080 shares compared to an average volume of 686,413 shares. The company currently carries a market capitalization of $149.093M and a beta of 0.43, reflecting relatively controlled volatility for a clinical-stage biotech stock. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 highlights substantial upside potential tied to future clinical and regulatory developments.

Mechanism of Action

Cardiol’s lead therapies are designed to target inflammatory signaling pathways associated with cardiac injury and disease progression. By modulating inflammasome activity and reducing pro-inflammatory cytokines such as IL-1 and IL-6, the company aims to address underlying drivers of inflammation linked to recurrent pericarditis, myocarditis, and other cardiovascular disorders.

Strategic Differentiation

Unlike some traditional anti-inflammatory approaches that broadly suppress immune activity, Cardiol’s strategy is intended to selectively reduce harmful inflammation while preserving normal immune function. This differentiated profile may offer advantages in long-term safety and tolerability, particularly for chronic cardiovascular conditions requiring extended treatment duration.

Outlook

As scientific understanding of cardiovascular inflammation continues to evolve, Cardiol’s mechanism-driven platform could strengthen its positioning within the biotech sector. Continued clinical validation may further support investor confidence and future partnership opportunities.

Oragenics Inc (OGEN)

Witnessing the stock’s movement on the chart, on May 11, 2026, Oragenics Inc (NYSEAMERICAN: OGEN) had a quiet start as it plunged -6.60% to $0.56. During the day, the stock rose to $0.60 and sank to $0.56. Taking a long-term approach, OGEN posted a 52-week range of $0.50-$9.60.

The Healthcare sector firm’s twelve-monthly sales growth has been 64.78% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time was 64.78%. This publicly-traded company’s shares outstanding now amount to $4.38 million, simultaneously with a float of $4.32 million. The organization now has a market capitalization of $2.52 million.

May 12, 2026
3 Stocks to Keep on Your Radar: Cardiol Therapeutics (CRDL), Dyadic International (DYAI), Jaguar Health (JAGX)

The biotechnology sector continues to demonstrate a strong link between clinical advancement and investor sentiment, with late-stage programs often serving as primary catalysts for valuation shifts. As therapies move closer to regulatory review, market focus intensifies on data integrity, study completion timelines, and the strength of underlying clinical endpoints.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is reinforcing its long-term investment profile through disciplined financial management, focused clinical execution, and a strategy aimed at maximizing future commercialization opportunities. As development-stage biotech companies navigate increasingly competitive capital markets, operational stability remains an important differentiator for investors.

Market Momentum

As of May 11, 2026, CRDL closed at $1.3350, up 1.14%, with trading volume of 370,080 shares versus an average volume of 686,413 shares. The company currently maintains a market capitalization of $149.093M and a beta of 0.43, reflecting relatively moderate volatility compared to many small-cap biotech peers. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.38 implies significant upside potential if upcoming milestones are achieved.

Financial and Operational Positioning

Cardiol has previously indicated that its cash resources are expected to support operations into 2027, providing the company with flexibility to continue advancing the Phase III MAVERIC trial while supporting broader pipeline development activities. A stable funding runway may reduce near-term financing pressure and allow management to remain focused on clinical execution.

Commercial Strategy

Management has also emphasized a partnership-oriented approach for future commercialization efforts. This strategy could enable Cardiol to leverage the resources, regulatory expertise, and global infrastructure of larger pharmaceutical companies while maintaining focus on clinical innovation within inflammatory cardiovascular disease.

Outlook

With ongoing clinical progress, disciplined operational management, and a pragmatic commercialization strategy, Cardiol appears increasingly well-positioned to pursue long-term value creation as it advances toward future regulatory and partnership milestones.

Dyadic International Inc, DE (DYAI)

Dyadic International Inc, DE (NASDAQ: DYAI) started the day on May 11, 2026, with a price decrease of -5.52% at $0.72. During the day, the stock rose to $0.79 and sank to $0.70. Taking a long-term approach, DYAI posted a 52-week range of $0.65-$1.35.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 7.84%. Meanwhile, its Annual Earnings per share during the time was 7.84%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 60.87%. This publicly-traded company’s shares outstanding now amount to $36.19 million, simultaneously with a float of $27.08 million. The organization now has a market capitalization of $26.39 million.

Jaguar Health Inc (JAGX)

As of May 11, 2026, Jaguar Health Inc (NASDAQ: JAGX) got off with the flyer as it spiked 10.00% to $3.3. During the day, the stock rose to $3.45 and sank to $2.87. Taking a more long-term approach, JAGX posted a 52-week range of $2.53-$327.60.

In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was 85.33%. Meanwhile, its Annual Earnings per share during the time was 85.33%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 99.51%. This publicly-traded company’s shares outstanding now amount to $0.40 million, simultaneously with a float of $0.28 million. The organization now has a market capitalization of $1.32 million.

May 12, 2026
3 Stocks Traders Are Watching: Nexgel (NXGL), SeaStar Medical (ICU), Cardiol Therapeutics (CRDL)

Healthcare equities often trade in cycles that reflect both scientific progress and capital market conditions. Periods of heightened enthusiasm tend to coincide with positive clinical readouts or regulatory breakthroughs, while consolidation phases may occur during interim data gaps. Despite this cyclical nature, long-term interest in innovative therapeutics continues to support sector engagement.

Nexgel Inc (NXGL)

Nexgel Inc (NASDAQ: NXGL) flaunted a 3.54% decline to $0.59, as the Stock market unbolted on May 08, 2026. During the day, the stock rose to $0.62 and sank to $0.59. Taking a long-term approach, NXGL posted a 52-week range of $0.56-$2.97.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -77.47%. Meanwhile, its Annual Earnings per share during the time were -77.47%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 197.37%. This publicly-traded company’s shares outstanding now amount to $8.14 million, simultaneously with a float of $6.60 million. The organization now has a market capitalization of $6.78 million.

SeaStar Medical Holding Corp (ICU)

Witnessing the stock’s movement on the chart, on May 08, 2026, SeaStar Medical Holding Corp (NASDAQ: ICU) had a quiet start as it plunged -7.61% to $4.49. During the day, the stock rose to $4.93 and sank to $4.35. Taking a long-term approach, ICU posted a 52-week range of $2.07-$13.40.

The Healthcare sector firm’s twelve-monthly sales growth has been -125.73% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time were -125.73%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 44.54%. This publicly-traded company’s shares outstanding now amount to $3.99 million, simultaneously with a float of $3.89 million. The organization now has a market capitalization of $17.93 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is positioning itself for broader long-term growth through the expansion of its pipeline into larger cardiovascular markets. By developing next-generation therapies targeting inflammation and fibrosis, the company is seeking to build a diversified platform capable of addressing major unmet needs in chronic heart disease.

Market Momentum

As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume of 578,846 shares compared to an average volume of 686,648 shares. The company currently carries a market capitalization of $147.418M and a beta of 0.43, reflecting relatively moderate volatility compared to many clinical-stage biotech peers. Shares remain within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 suggests significant upside potential tied to future pipeline progress.

Pipeline Expansion: CRD-38

Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience and expand applicability into broader cardiovascular conditions, including heart failure. The therapy targets inflammation and fibrosis, two major biological drivers associated with worsening cardiac function and disease progression.

Strategic Opportunity

The recent publication announcement involving CardiolRx™ Phase II data in the Journal of the American Heart Association may further strengthen confidence in Cardiol’s broader anti-inflammatory platform. Positive validation of its scientific approach could support future development efforts for CRD-38 as the company expands beyond recurrent pericarditis into larger market opportunities.

Outlook

As CRD-38 advances toward future clinical development, the asset could emerge as an important secondary value driver for Cardiol. Continued progress across the pipeline may strengthen the company’s long-term growth profile and strategic positioning within cardiovascular biotechnology.

May 11, 2026
3 Stocks Worth Watching Today: Cardiol Therapeutics (CRDL), Fortress Biotech (FBIO), Dogwood Therapeutics (DWTX)

Investor attention in the healthcare sector continues to be shaped by the balance between near-term clinical catalysts and long-term commercial potential. While short-term price action can be influenced by sentiment and liquidity conditions, sustained valuation growth is typically driven by meaningful clinical validation. This dynamic keeps focus firmly on programs advancing through pivotal stages of development.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is entering an increasingly important stage of development as growing scientific validation supports the advancement of its lead cardiovascular therapy. For clinical-stage biotech companies, publication in respected peer-reviewed journals can significantly strengthen credibility with both investors and the broader medical community.

Market Momentum

As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume reaching 578,846 shares compared to an average volume of 686,648 shares. The company currently holds a market capitalization of $147.418M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech stock. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 suggests substantial upside potential tied to future clinical milestones.

Clinical Validation

Cardiol recently announced that Phase II results for CardiolRx™ in recurrent pericarditis will be published in the Journal of the American Heart Association. The study demonstrated rapid and sustained reductions in pain and inflammation, particularly among patients with more severe disease at baseline. Researchers also observed fewer annual recurrence episodes, alongside favorable safety and tolerability findings.

Impact on Late-Stage Development

The Phase II data continues to support the advancement of the ongoing Phase III MAVERIC trial, which has now enrolled more than 75% of participants. Importantly, the earlier findings also helped shape the design of the pivotal study, strengthening the clinical rationale behind CardiolRx™’s development strategy.

Outlook

With a peer-reviewed publication adding external validation to its clinical profile, Cardiol appears increasingly well-positioned as it advances toward key regulatory and commercialization milestones.

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (NASDAQ: FBIO) started the day on May 08, 2026, with a price decrease of -0.42% at $2.39. During the day, the stock rose to $2.44 and sank to $2.36. Taking a long-term approach, FBIO posted a 52-week range of $1.60-$4.53.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 62.98%. Meanwhile, its Annual Earnings per share during the time was 62.98%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is -900.00%. This publicly-traded company’s shares outstanding now amount to $31.36 million, simultaneously with a float of $24.35 million. The organization now has a market capitalization of $76.96 million.

Dogwood Therapeutics Inc (DWTX)

As of May 08, 2026, Dogwood Therapeutics Inc (NASDAQ: DWTX) got off with the flyer as it spiked 5.77% to $1.65. During the day, the stock rose to $1.66 and sank to $1.55. Taking a long-term approach, DWTX posted a 52-week range of $1.28-$9.50.

In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was 25.53%. Meanwhile, its Annual Earnings per share during the time was 25.53%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 85.69%. This publicly-traded company’s shares outstanding now amount to $33.40 million, simultaneously with a float of $33.40 million. The organization now has a market capitalization of $55.11 million.

May 11, 2026